Last year was a big one for Axsome Therapeutics (NASDAQ: AXSM). The biotech company specialized in central nervous system conditions launched its first two products and saw its share price increase by 100%. But a lot more could be on the horizon.

Axsome is starting to grow revenue thanks to those first two products. And its pipeline, with all late-stage candidates, could make it a multiproduct company sooner rather than later. In fact, Axsome may undergo a significant transformation in just three years. Let's take a closer look at what we might expect from this up-and-coming company.

First, a look at Axsome's situation today. The company sells sleep disorder drug Sunosi and antidepressant Auvelity. Axsome acquired the former from Jazz Pharmaceuticals and developed the latter in house. Both of these products have enormous potential. Axsome predicts U.S. peak sales for Sunosi could reach $500 million and sales of Auvelity may reach $3 billion.

Continue reading

Source Fool.com